help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 12, No. 1, 79-89, January 2007; doi:10.1634/theoncologist.12-1-79
© 2007 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Crivellari, G.
Right arrow Articles by Aversa, S. M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Crivellari, G.
Right arrow Articles by Aversa, S. M. L.

Lung Cancer

Increasing Chemotherapy in Small-Cell Lung Cancer: From Dose Intensity and Density to Megadoses

Gino Crivellari, Silvio Monfardini, Silvia Stragliotto, Dario Marino, Savina Maria Luciana Aversa

Unità Operativa di Oncologia Medica, Istituto Oncologico Veneto (IOV) IRCCS, Padova, Italy

Key Words. Small-cell lung cancer • Dose intensity • Dose density • Megadose

Correspondence: Gino Crivellari, M.D., Unità Operativa di Oncologia Medica, Istituto Oncologico Veneto (IOV) IRCCS, via Gattamelata 64, 35128 Padova, Italy. Telephone: 39-049-8215931; Fax: 39-049-8215932; e-mail: gino.crivellari{at}unipd.it

The hypothesis that increasing cytotoxic dose intensity will improve cancer cure rates is compelling. Although supporting evidence for this hypothesis has accrued for several tumor types, including lymphomas, breast cancer, and testicular cancers, it remains unproven. Small-cell lung cancer is extremely chemo- and radiosensitive, with a response rate of 80% achieved routinely, but few patients are cured by chemoradiotherapy. In this setting, increased cytotoxic dose intensity might improve cure rates. The finding that response rates in small-cell lung cancer correlate with received cytotoxic dose intensity merely confirms that "less is worse" and "more is better." Within conventional ranges, dose intensity can be increased with the support of hematopoietic growth factors and/or by shortening treatments intervals; however, dose intensity could be increased by only 20%–30%, and a survival advantage has not been clearly demonstrated. Given its high chemosensitivity, small-cell lung cancer was one of the first malignancies deemed suitable for increasing dose intensity and even for the use of a megadose with the support of autologous bone marrow transplantation. Some interest is emerging again due to improvements in supportive care, such as the availability of hematopoietic growth factors and peripheral blood progenitor cells.




This article has been cited by other articles:


Home page
 Mayo Clin Proc.Home page
T. Sher, G. K. Dy, and A. A. Adjei
Small Cell Lung Cancer
Mayo Clin. Proc., March 1, 2008; 83(3): 355 - 367.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2007 by AlphaMed Press.